Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
Date:7/31/2012

reported for the second quarter of 2011.  Net income for the second quarter of 2012 includes total stock-based compensation expense of $3.9 million, compared to $4.0 million for the second quarter of 2011.

As of June 30, 2012, Auxilium had $181.3 million in cash, cash equivalents and short-term investments, compared to $163.1 million at March 31, 2012, and no debt.

Updated Guidance:

  • The Company is increasing full year 2012 guidance for global Testim revenues from the previously stated guidance of a range of $225 to $235 million to a range of $245 to $255 million.
  • The Company is maintaining full year 2012 guidance for XIAFLEX U.S. revenues of $55 to $65 million.
  • The Company is decreasing full year 2012 guidance for XIAFLEX Ex.-U.S/contract revenues from the previously stated guidance of a range of $13 to $15 million to a range of $10 to $12 million and full year global XIAFLEX revenues from the previously stated guidance of a range of $68 to $80 million to a range of $65 to $77 million
  • The Company is increasing full year 2012 guidance for total net revenues from the previously stated guidance of a range of $293 to $315 million to a range of $310 to $332 million.
  • The Company is decreasing full year 2012 guidance for R&D from the previously stated guidance of a range of $55 to $65 million to a range of $45 to $55 million.
  • The Company is increasing full year 2012 guidance for SG&A from the previously stated guidance of a range of $180 to $190 million to a range of $200 to $210 million.
  • The Company is increasing full year 2012 net income guidance from the previously stated guidance of a range of $(5) to $(10) million to a range of $0 to $5 million for the year.  See Table 4 attached for further details on guidance.
  • Conference Call
    Auxilium will hold a conference call today, July 31, 2012 at 10:00 a.m. ET, to discuss second quarter 2012 results. The presentati
    '/>"/>

    SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
    2. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
    3. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
    4. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
    5. Auxilium Pharmaceuticals to Announce First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10, 2012
    6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
    7. Jason Pharmaceuticals, Inc. Reaches Proposed Consent Agreement with FTC
    8. Avion Pharmaceuticals, LLC., Launches Prenate Mini
    9. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    10. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
    11. Acella Pharmaceuticals, LLC, files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration for Topical Corticosteroids Lotion
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/2/2015)... March 2, 2015  BC Technical, the nation,s ... acquired Eclipse Systems, a Nuclear Imaging service company ... part of their ongoing vision to provide the ... rate, BC Technical continues to expand their reach ... to add valuable resources and knowledge in addition ...
    (Date:3/2/2015)... Calif. , March 2, 2015  DURECT ... its Epigenomic Regulator Program, and the successful completion ... program,s lead product candidate DUR-928.  DUR-928 is an ... have broad applicability in metabolic diseases such as ... (NASH), and in acute organ injuries such as ...
    (Date:3/2/2015)... -- Intrexon Corporation (NYSE: XON ), a ... quarter and full year results for 2014.  ... , Acquired ActoGeniX, a European clinical stage biopharmaceutical ... and other innovative products.  Its proprietary TopAct™ platform ... Lactococcus lactis ) to generate biologically-contained ActoBiotics™ for ...
    Breaking Medicine Technology:BC Technical Acquires Eclipse Systems 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24
    ... 14, 2012  The Consumer Healthcare Products Association (CHPA) ... into law House Bill 2263—anti-meth legislation authored by ... 23rd state to adopt real-time, stop-sale technology known ... The proven system—in a process similar ...
    ... SCHLIEREN-ZURICH, Switzerland, May 14, 2012 The ALS ... it has entered into collaboration with Neurotune ... Neuron or Lou Gehrig,s disease). (Photo: ... "Maintaining the health of motor neurons ...
    Cached Medicine Technology:CHPA Applauds Arizona's Adoption Of HB 2263 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 3
    (Date:3/2/2015)... Surgeons at the Forbes Hospital ... Network, are exploring an innovative use of Google ... Zonal Reminder (VIZR), to assist in the care of ... is a wearable technology with an optical head-mounted display ... communicate with the Internet via natural language voice commands. ...
    (Date:3/2/2015)... March 02, 2015 Ticket Down is ... the Hollywood Bowl . This popular site has reduced ... promo code JIMMY-BUFFETT-2015 for added savings. , Parrotheads in ... performer will be headlining at the Hollywood Bowl for ... be on Thursday, October 22nd and it will be ...
    (Date:3/2/2015)... Doctors in Novara, Italy have found that ... outcomes for people with mesothelioma than other clinical factors. ... new study on the Surviving Mesothelioma website. , ... Piedmont followed the cases of 172 mesothelioma patients ... fluid. , “Persistent lung expansion after pleural talc ...
    (Date:3/2/2015)... 2015 Burns Engineering's Lab-to-Lab Calibration ... Secondary Standard Platinum Resistance Thermometers (SSPRTs) and industrial ... or less . . . guaranteed. ... (Lab Code 200706-0), ISO 9001 and 17025 Certified ... is -196°C to 500°C, both ITS-90 and Callendar-van ...
    (Date:3/2/2015)... The minimally invasive surgical instruments market is ... to reach $14,133.0 million by 2019 from $10,526.2 ... advantages of minimally invasive surgeries over traditional open ... surgeries and increasing number of surgical procedures among ... invasive surgical instruments market. , For More Details ...
    Breaking Medicine News(10 mins):Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2
    ... In a decision of broad impact to medical malpractice ... refused to apply the state,s "cap" on non-economic damages ... when the Maryland General Assembly revised the damage cap ... could recover from negligent doctors and hospitals, the legislature ...
    ... April 21 Hudson Institute is pleased to welcome ... of Health and Human Services (HHS) under George W. ... Troy will write on health care, medical innovation, and ... around the corner, we are very fortunate to have ...
    ... Cancer Research,s 100th Annual Meeting 2009 -SOUTH SAN FRANCISCO, ... (Nasdaq: PARD ), a biopharmaceutical company focused ... from a Phase 1 clinical study of an oral ... showed that the bioavailability of oral picoplatin is nearly ...
    ... device for the treatment of depression named one ... 21 - NeuroStar(R) TMS (Transcranial Magnetic Stimulation) Therapy ... treatment cleared by the FDA for Major Depressive ... Design Excellence Award (MDEA). The award will be ...
    ... 21 Frost & Sullivan presented ... Pacific,s Healthcare sector at the 2009 Frost ... Awards held today at the InterContinental hotel in ... consecutive year, the awards banquet recognised companies across ...
    ... HRC ) fiscal 2009 second quarter earnings release will ... participate in a webcast the following morning on May 5, 2009 ... Holdings, Inc.,s Fiscal 2009 Second Quarter Release for the quarter ended ... NYSE close on Monday, May 4, 2009. The release will ...
    Cached Medicine News:Health News:Judge Holds Maryland Damages Cap Not Applicable to Malpractice Cases 2Health News:Judge Holds Maryland Damages Cap Not Applicable to Malpractice Cases 3Health News:Former HHS Deputy Secretary Tevi Troy Joins Hudson Institute 2Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 2Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 3Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 4Health News:Photos: NeuroStar TMS Therapy(R) Recipient of Medical Design Excellence Award 2Health News:Photos: NeuroStar TMS Therapy(R) Recipient of Medical Design Excellence Award 3Health News:Outstanding Healthcare Companies in Asia Pacific Honored 2Health News:Outstanding Healthcare Companies in Asia Pacific Honored 3Health News:Outstanding Healthcare Companies in Asia Pacific Honored 4Health News:Outstanding Healthcare Companies in Asia Pacific Honored 5Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Second Quarter Earnings Webcast 2
    ... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
    ... Centra-GP6R general purpose centrifuges offer high-volume versatility ... rotor options, making them ideal for a ... Versatility , Four- or six-place sealed ... oil tube rotors offered , Lare capacity ...
    ... Centrifuges feature powerful, maintenance-free motors, ... of rotors for unparalleled application ... in one: a high capacity ... harvesting; a high-speed centrifuge for ...
    ... MicroCentrifuge Two Strip Rotor hold 16 0.2ml ... with). Simply close the polycarbonate lid to ... open. Starts and stops in seconds. Maximum ... g. Only five inches in diameter. Also ...
    Medicine Products: